Newsfiscal.ai
FDA Lifts Clinical Hold on Aardvark Therapeutics' ARD-101
· Published
Article summary
The U.S. Food and Drug Administration has lifted the clinical hold on Aardvark Therapeutics' investigational new drug application for ARD-101, intended for treating hyperphagia in Prader-Willi Syndrome.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…